Impact of Glycemic Control Strategies on the Progression of Diabetic Peripheral Neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial demonstrated similar long-term clinical effectiveness of insulin-sensitizing (IS) versus insulin-providing (IP) treatments for type 2 diabetes on cardiovascular outcomes in a cohort with documented coronary artery disease. We evaluated the effects of randomized glycemic control strategy (IS vs. IP) on the prevalence and incidence of diabetic peripheral neuropathy (DPN). RESEARCH DESIGN AND METHODS: DPN (defined as Michigan Neuropathy Screening Instrument [MNSI] clinical examination score >2) was assessed at baseline and yearly for 4 years. DPN prevalence and incidence were compared by intention-to-treat modeling by logistic generalized estimating equation models for prevalence and Kaplan-Meier estimates and Cox regression models for incidence rates. RESULTS: Results are reported for 2,159 BARI 2D participants (70% males) with valid baseline and at least one follow-up MNSI score (mean age 62 ± 9 years, mean HbA1c 7.7 ± 1.6%, diabetes duration 10 ± 9 years). There were no differences in the prevalence of DPN between the IS and the IP groups throughout the 4 years of follow-up. In 1,075 BARI 2D participants with no DPN at baseline, the 4-year cumulative incidence rate of DPN was significantly lower in the IS (66%) than in the IP (72%) strategy group (P = 0.02), which remained significant after adjusting for the in-trial HbA1c (P = 0.04). In subgroup analyses, IS strategy had a greater benefit in men (hazard ratio 0.75 [99% CI 0.58–0.99], P < 0.01). CONCLUSIONS: Among patients with type 2 diabetes followed for up to 4 years during BARI 2D, a glycemic control therapy with IS significantly reduced the incidence of DPN compared with IP therapy and may add further benefit for men.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A combination of typical symptomatology and symmetrical distal sensory loss, or typical signs in the absence of symptoms, in a person with DM is highly suggestive of DPN and may not require additional evaluations or referral.547,565–567”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [566]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The diagnosis of DPN is principally a clinical one.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [566]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Xu, H., Barnes, G. T., Yang, Q., Tan, G., Yang, D., Chou, C. J., Sole, J., Nichols, A., Ross, J. S., Tartaglia, L. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319451 · Cited by 6,760 · cited 1×
“In addition, the weight gain observedwith the IP treatment could have contributed to an increase in chronic inflammation and oxidative stress (36).”
BackgroundTesfaye, S., Boulton, A. J. M., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., Lauria, G., Malik, R. A., Spallone, V., Vinik, A., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1303 · Cited by 2,690
The global burden of diabetic foot disease
Boulton, A. J., Vileikyte, L., Ragnarson-Tennvall, G., & Apelqvist, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67698-2 · Cited by 2,566 · cited 2×
“The 3-year survival rate in patients with DPN is 20% less than in age- and sex-matched diabetic patients without this complication (1,2).”
BackgroundA Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805796 · Cited by 1,939
Feldman, E. L., Stevens, M. J., Thomas, P. K., Brown, M. B., Canal, N., & Greene, D. A. (1994) · Diabetes Care · doi:10.2337/diacare.17.11.1281 · Cited by 1,293 · cited 4×
“2 was shown to have the highest sensitivity and specificity of correctly classifying DPN (11,13); therefore, in the present analysis, DPN was defined as an MNSI clinical examination score of .”
BackgroundMethodInfluentialHaffner, S. M., Greenberg, A. S., Weston, W. M., Chen, H., Williams, K., & Freed, M. I. (2002) · Circulation · doi:10.1161/01.cir.0000025403.20953.23 · Cited by 884 · cited 1×
“In this respect, experimental and human data demonstrate that TZDs may reduce inflammatory responses through NF-kB blockade (20,21).”
BackgroundEnhanced glucose control for preventing and treating diabetic neuropathy
Callaghan, B. C., Little, A. A., Feldman, E. L., & Hughes, R. A. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007543.pub2 · Cited by 584
Cited by
Diabetic neuropathy: A position statement by the American Diabetes Association
Pop-Busui, R., Boulton, A. J. M., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017) · Diabetes Care · doi:10.2337/dc16-2042 · Cited by 2,602
“DSPN may be present in at least 10%–15% of newly diagnosed patients with type 2 diabetes (44,45), with rates increasing to 50% after 10 years of disease duration (25,26).”
BackgroundMethodSelf-citationFeldman, E. L., Callaghan, B. C., Pop-Busui, R., Zochodne, D. W., Wright, D. E., Bennett, D. L., Bril, V., Russell, J. W., & Viswanathan, V. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0092-1 · Cited by 1,697
Self-citationSelvarajah, D., Kar, D., Khunti, K., Davies, M. J., Scott, A. R., Walker, J., & Tesfaye, S. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30081-6 · Cited by 556
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citationPathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy
Sloan, G., Selvarajah, D., & Tesfaye, S. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00496-z · Cited by 534
Prevention and treatment of diabetic foot ulcers
Lim, J. Z. M., Ng, N. S. L., & Thomas, C. (2017) · Journal of the Royal Society of Medicine · doi:10.1177/0141076816688346 · Cited by 486
“Increasing evidence has shown that intensive glycaemic control delays the onset and slows the progression of diabetic retinopathy, nephropathy and neuropathy in patients with insulin-dependent diabetes mellitus.(17,18) However, intensive glycaemic control must also be accompanied by cautious monitoring as tighter cont…”
Background11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes−2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s011 · Cited by 460
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s011 · Cited by 398
“neuropathy over 4 years than those treated with insulin/sulfonylurea (117).”
Background11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s011 · Cited by 395
Diabetic Neuropathy: Mechanisms, Emerging Treatments, and Subtypes
Albers, J. W., & Pop-Busui, R. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0473-5 · Cited by 357
Self-citationChallenges of neuropathic pain: focus on diabetic neuropathy
Rosenberger, D. C., Blechschmidt, V., Timmerman, H., Wolff, A., & Treede, R.-D. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02145-7 · Cited by 325
Glucose Control and Diabetic Neuropathy: Lessons from Recent Large Clinical Trials
Ang, L., Jaiswal, M., Martin, C., & Pop-Busui, R. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0528-7 · Cited by 303
Self-citation10. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s010 · Cited by 302
12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gibbons, C. H., Giurini, J. M., Hilliard, M. E., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s012 · Cited by 207
Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015
Papanas, N., & Ziegler, D. (2015) · The Review of Diabetic Studies · doi:10.1900/rds.2015.12.48 · Cited by 207
Understanding Diabetic Neuropathy: Focus on Oxidative Stress
Pang, L., Lian, X., Liu, H., Zhang, Y., Li, Q., Cai, Y., Ma, H., & Yu, X. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/9524635 · Cited by 184
Painful and Painless Diabetic Neuropathies: What Is the Difference?
Shillo, P., Sloan, G., Greig, M., Hunt, L., Selvarajah, D., Elliott, J., Gandhi, R., Wilkinson, I. D., & Tesfaye, S. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1150-5 · Cited by 183
10. Microvascular Complications and Foot Care
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s013 · Cited by 181
“In a post hoc analysis, participants, particularly men, in the Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes (BARI 2D) trial treated with insulin sensitizers had a lower incidence of distal symmetric polyneuropathy over 4 years than those treated with insulin/sulfonylurea (86).”
Background12. Retinopathy, Neuropathy, and Foot Care: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s012 · Cited by 177
12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Callaghan, B. C., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s012 · Cited by 176
12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gibbons, C. H., Giurini, J. M., Hilliard, M. E., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s012 · Cited by 169
Xu, F., Zhao, L.-H., Su, J.-B., Chen, T., Wang, X.-Q., Chen, J.-F., Wu, G., Jin, Y., & Wang, X.-H. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-139 · Cited by 159
“[39] showed a glycemic control therapy with insulin-sensitizing significantly reduced the incidence of DPN compared with insulin-providing therapy among patients with type 2 diabetes followed for up to 4 years during the study.”
ResultYang, H., Sloan, G., Ye, Y., Wang, S., Duan, B., Tesfaye, S., & Gao, L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00929 · Cited by 151
“recently found that patients with type 2 diabetes treated with insulin sensitizing therapies had a significantly reduced incidence of DPN compared with insulin providing treatments (10, 95).”
BackgroundCohort profile: the German Diabetes Study (GDS)
The GDS Group, Szendroedi, J., Saxena, A., Weber, K. S., Strassburger, K., Herder, C., Burkart, V., Nowotny, B., Icks, A., Kuss, O., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0374-9 · Cited by 151
Khawaja, N. M., Abu-Shennar, J. A., Saleh, M., Dahbour, S. S., Khader, Y. S., & Ajlouni, K. M. (2018) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-018-0309-6 · Cited by 162
HbA1c variability and diabetic peripheral neuropathy in type 2 diabetic patients
Su, J.-B., Zhao, L.-H., Zhang, X.-L., Cai, H.-L., Huang, H.-Y., Xu, F., Chen, T., & Wang, X.-Q. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0693-0 · Cited by 146
“[47] revealed that the occurrence of DPN in patients given insulin injections was more than in those taking insulin-sensitizing agents.”
Background9. Microvascular Complications and Foot Care
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc15-s012 · Cited by 137
Diabetic Sensory and Motor Neuropathy
Vinik, A. I. (2016) · New England Journal of Medicine · doi:10.1056/nejmcp1503948 · Cited by 113
Role of Magnesium in Type 2 Diabetes Mellitus
Feng, J., Wang, H., Jing, Z., Wang, Y., Cheng, Y., Wang, W., & Sun, W. (2019) · Biological Trace Element Research · doi:10.1007/s12011-019-01922-0 · Cited by 128
12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., Callaghan, B. C., ChallaSivaKanaka, S., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s012 · Cited by 214
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease
Lo, C., Toyama, T., Wang, Y., Lin, J., Hirakawa, Y., Jun, M., Cass, A., Hawley, C. M., Pilmore, H., Badve, S. V., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011798.pub2 · Cited by 100
Management of diabetic neuropathy
Cernea, S., & Raz, I. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154867 · Cited by 115
Diabetic peripheral neuropathy essentials: a narrative review
Chang, M. C., & Yang, S. (2023) · Annals of Palliative Medicine · doi:10.21037/apm-22-693 · Cited by 135
Out, M., Kooy, A., Lehert, P., Schalkwijk, C. A., & Stehouwer, C. D. A. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.11.001 · Cited by 84
Diabetic Neuropathy: Pathophysiology Review
Strand, N. H., Anderson, M. A., Attanti, S., Gill, B., Wie, C. S., Dawodu, A., Pagan-Rosado, R. D., Harbell, M. W., & Maloney, J. A. (2024) · Current Pain and Headache Reports · doi:10.1007/s11916-024-01243-5 · Cited by 110
Ponirakis, G., Abdul‐Ghani, M. A., Jayyousi, A., Almuhannadi, H., Petropoulos, I. N., Khan, A., Gad, H., Migahid, O., Megahed, A., DeFronzo, R. A., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001420 · Cited by 83
Corneal confocal microscopy for the diagnosis of diabetic autonomic neuropathy
Tavakoli, M., Begum, P., McLaughlin, J. T., & Malik, R. A. (2014) · Muscle & Nerve · doi:10.1002/mus.24553 · Cited by 81
Improvement in Neuropathy Outcomes With Normalizing HbA1c in Patients With Type 2 Diabetes
Ishibashi, F., Taniguchi, M., Kosaka, A., Uetake, H., & Tavakoli, M. (2018) · Diabetes Care · doi:10.2337/dc18-1560 · Cited by 86
Spectrum of Diabetic Neuropathy: New Insights in Diagnosis and Treatment
Dillon, B. R., Ang, L. P., & Pop‐Busui, R. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-033114 · Cited by 105
Self-citationMoon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Pharmacological treatment of diabetic peripheral neuropathy.
Cohen, K., Shinkazh, N., Frank, J., Israel, I., & Fellner, C. (2015) · PubMed · Cited by 103
Current Pharmacological Treatment of Painful Diabetic Neuropathy: A Narrative Review
Ardeleanu, V., Alexandra Monica, T. O. M. A., Pafili, K., Παπάνας, Ν., Motofei, I. G., Diaconu, C. C., Rizzo, M., & Stoian, A. P. (2020) · Medicina · doi:10.3390/medicina56010025 · Cited by 86
“In a post-hoc analysis of the BARI 2D clinical trial (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes), subjects treated with insulin sensitizers exhibited a reduced incidence of DSPN at 4 years, as compared with those receiving insulin or sulphonylureas [16].”
MethodBril, V., Breiner, A., Perkins, B. A., & Zochodne, D. W. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.028 · Cited by 98
Self-citationYapislar, H., & Gurler, E. B. (2024) · Biomedicines · doi:10.3390/biomedicines12091958 · Cited by 64
“Inflammatory processes play a role in the development and progression of diabetic neuropathy [93].”
BackgroundMalik, R. A., Aldinc, E., Chan, S.-P., Deerochanawong, C., Hwu, C., Rosales, R. L., Yeung, C., Fujii, K., & Parsons, B. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0536-5 · Cited by 62
“Changes in lifestyle, such as exercise, may improve neuropathic symptoms including pain [29], glycemic control may reduce the risk of developing DPN [30] and slow its progression [31], but it has not been shown to impact on Fig.”
BackgroundHu, Y.-M., Zhao, L.-H., Zhang, X.-L., Cai, H.-L., Huang, H.-Y., Xu, F., Chen, T., Wang, X.-Q., Guo, A.-S., Li, J.-A., et al. (2018) · Endocrine · doi:10.1007/s12020-018-1546-z · Cited by 57
HbA1c and Lower Extremity Amputation Risk in Patients With Diabetes
Zhou, Z., Liu, Y., Chen, H., Yang, H.-L., & Liu, F. (2015) · The International Journal of Lower Extremity Wounds · doi:10.1177/1534734615593190 · Cited by 57
Update on the Management of Diabetic Neuropathy
Ang, L., Cowdin, N., Mizokami-Stout, K., & Pop-Busui, R. (2018) · Diabetes Spectrum · doi:10.2337/ds18-0036 · Cited by 55
“There is also robust evidence for CAN prevention with intensive glucose control designed to achieve near-normal glycemia in type 1 diabetes (11), as documented by a 45% reduction in the risk of incident CAN, assessed with highly reproducible and sensitive tests in a large sample during the Diabetes Control and Complic…”
BackgroundSelf-citationDiabetes mellitus type 2 in adults
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Шамхалова, М. Ш., Sukhareva, O. Y., Galstyan, G. R., Tokmakova, A. Y., Nikonova, T. V., Surkova, E. V., Кононенко, И. В., et al. (2020) · Diabetes Mellitus · doi:10.14341/dm12507 · Cited by 69
Pop‐Busui, R., Backlund, J. C., Bebu, I., Braffett, B. H., Lorenzi, G., White, N. H., Lachin, J. M., Soliman, E. Z., & DCCT/EDIC Research Group (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13635 · Cited by 52
Self-citationThe conundrum of diabetic neuropathies—Past, present, and future
Ang, L. P., Mizokami‐Stout, K., Eid, S., Elafros, M. A., Callaghan, B. C., Feldman, E. L., & Pop‐Busui, R. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108334 · Cited by 66
Self-citationAtmaca, A. A., Ketenci, A., Şahin, İ., Şengün, İ. Ş., Öner, R. İ., Tilki, H. E., Adaş, M., Soyleli, H., & Demir, T. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1380929 · Cited by 69
Cardoso, C. R. L., Moran, C. B. M., Marinho, F. D. S., Ferreira, M. T., & Salles, G. F. (2015) · Diabetologia · doi:10.1007/s00125-015-3658-9 · Cited by 52
Santos, T. R. M., de Melo, J. V., Leite, N. C., Salles, G. F., & Cardoso, C. R. L. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.05.010 · Cited by 53
McIllhatton, A., Lanting, S. M., Lambkin, D., Leigh, L., Casey, S. L., & Chuter, V. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002528 · Cited by 57
Axonopathy in peripheral neuropathies: Mechanisms and therapeutic approaches for regeneration
Landowski, L. M., Dyck, P. J., Engelstad, J. K., & Taylor, B. V. (2016) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2016.04.006 · Cited by 54
Yan, P., Xu, Y., Zhang, Z., Gao, C., Zhu, J., Li, H., & Wan, Q. (2018) · Cytokine · doi:10.1016/j.cyto.2018.10.007 · Cited by 44
Tang, Y., Lenzini, P. A., Pop-Busui, R., Ray, P. R., Campbell, H., Perkins, B. A., Callaghan, B., Wagner, M. J., Motsinger-Reif, A. A., Buse, J. B., et al. (2019) · Diabetes · doi:10.2337/db19-0109 · Cited by 44
Self-citationWilliams, K., Burns, K. A., Constantino, M., Shackel, N. A., Prakoso, E., Wong, J., Wu, T., George, J., McCaughan, G. W., & Twigg, S. M. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.06.015 · Cited by 45
“, 2011) and also how agents that are known to be insulin sensitisers, including metformin and thiazolidinediones,might reduce the incidence of diabetic peripheral neuropathy when compared with insulin or insulin secretagogues, each after adjusting for differences in glycemic control (Pop-Busui et al., 2013).”
BackgroundPrevalence and management of diabetic neuropathy in secondary care in Qatar
Ponirakis, G., Elhadd, T. A., Chinnaiyan, S., Dabbous, Z., Siddiqui, M., Almuhannadi, H., Petropoulos, I. N., Khan, A., Ashawesh, K., Dukhan, K., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3286 · Cited by 48
Ponirakis, G., Elhadd, T. A., Chinnaiyan, S., Hamza, A. H., Sheik, S., Kalathingal, M. A., Anodiyil, M. S., Dabbous, Z., Siddique, M. A., Almuhannadi, H., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13388 · Cited by 44
Zhang, Q., Ji, L., Zheng, H., Li, Q., Qian, X., Sun, W., Zhu, X., Li, Y., Lü, B., Liu, X., et al. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.09.015 · Cited by 44
The Prevalence of Diabetic Microvascular Complications in China and the USA
Lin, Y. K., Gao, B., Liu, L., Ang, L. P., Mizokami‐Stout, K., Pop‐Busui, R., & Zhang, L. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01387-3 · Cited by 44
Self-citationKang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 84
Diabetes and Peripheral Nerve Disease
Zilliox, L. A. (2021) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2020.12.001 · Cited by 42
Mather, K. J., Bebu, I., Baker, C., Cohen, R. M., Crandall, J. P., DeSouza, C., Green, J. B., Kirkman, M. S., Krause-Steinrauf, H., Larkin, M., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108235 · Cited by 34
Self-citationGu, Y., Dennis, S. M., Kiernan, M. C., & Harmer, A. R. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3099 · Cited by 38
Alpha-lipoic acid for diabetic peripheral neuropathy
Băicuş, C., Purcărea, A., von Elm, E. B., Delcea, C., & Furtunescu, F. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012967.pub2 · Cited by 52
A potent weighted risk model for evaluating the occurrence and severity of diabetic foot ulcers
Shi, L., Wei, H., Zhang, T., Li, Z., Chi, X., Liu, D., Chang, D., Zhang, Y., Wang, X., & Zhao, Q. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00711-x · Cited by 32
“Increasing evidence showed that intensive glycemic control delayed the onset and progression of diabetic retinopathy, nephropathy, and neuropathy in patients with insulin-dependent diabetes [34, 35], and slow progression of neuropathy in some patients with type 2 diabetes [36].”
BackgroundPonirakis, G., Abdul‐Ghani, M. A., Jayyousi, A., Zirie, M. A., Qazi, M., Almuhannadi, H., Petropoulos, I. N., Khan, A., Gad, H., Migahid, O., et al. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13544 · Cited by 32
Galiero, R., Ricciardi, D., Pafundi, P. C., Todisco, V., Tedeschi, G., Cirillo, G., & Sasso, F. C. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108856 · Cited by 26
Peripheral sensory neuropathy in type 2 diabetes patients: A case control study in Accra, Ghana
Yeboah, K., Puplampu, P., Boima, V., Antwi, D. A., Gyan, B., & Amoah, A. G. B. (2016) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2016.07.001 · Cited by 31
Ahrary, Z., Khosravan, S., Alami, A., & Nesheli, M. N. (2020) · Clinical Rehabilitation · doi:10.1177/0269215520914067 · Cited by 25
Acrolein-inducing ferroptosis contributes to impaired peripheral neurogenesis in zebrafish
Qi, H., Kan, K., Sticht, C., Bennewitz, K., Li, S., Qian, X., Poschet, G., & Krøll, J. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1044213 · Cited by 23
Diabetic Polyneuropathy – Advances in Diagnosis and Intervention Strategies
Tesfaye, S. H., & SLOAN, G. P. (2020) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2020.16.1.15 · Cited by 30
“There was a significant association between changes in the Michigan Neuropathy Screening Instrument (MNSI) questionnaire and changes in body weight, HbA1c and serum lipids.(41) Moreover, a study by the Diabetes Prevention Program Research Group (n=2,890) showed that lifestyle interventions improved autonomic nervous s…”
BackgroundGogan, A., Potre, O., Avram, V. F., Andor, M., Căruntu, F. R., & Timar, B. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030671 · Cited by 35
“…of diabetic peripheral neuropathy and factors such as age, length of diabetes disease, height, HbA1c, smoking, proliferative or background diabetic retinopathy, high-density lipoprotein cholesterol, and cardiovascular disease were found throughout the EURODIAB IDDM Complications Study [16].”
Li, J., Tong, Y., Zhang, Y., Tang, L., Lv, Q., Zhang, F., Hu, R., & Tong, N. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.12.006 · Cited by 27
Chang, K., Pai, Y., Lin, C., Lee, I., & Chang, M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0287373 · Cited by 29
Screening and Treatment by the Primary Care Provider of Common Diabetes Complications
Gilbert, M. P. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.09.002 · Cited by 27
Guo, W., Zhou, Q., Jia, Y., & Xu, J. (2019) · Biological Trace Element Research · doi:10.1007/s12011-019-01747-x · Cited by 21
Association of arterial stiffness and neuropathy in diabetes: a systematic review and meta-analysis
Beros, A. L., Sluyter, J., & Scragg, R. K. R. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003140 · Cited by 23
Issues and challenges in diabetic neuropathy management: A narrative review
Ismail, C. A. N. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i6.741 · Cited by 31
Galstyan, G. R., Starostina, E. G., Yakhno, N. N., Владимировна, Г. И., Churyukanov, M. V., Strokov, I. A., Tokmakova, A. Y., Kukushkin, M. L., Martynov, A. I., & Shestakova, M. V. (2019) · Diabetes Mellitus · doi:10.14341/dm9625 · Cited by 25
Challenges in Diabetic Micro-Complication Management: Focus on Diabetic Neuropathy
Ansari, P., Hannan, J. M. A., Azam, S., & Jakaria, M. (2021) · International Journal of Translational Medicine · doi:10.3390/ijtm1030013 · Cited by 22
The Epidemiology of Diabetic Neuropathy
Hansen, C. S., Määttä, L. L., Andersen, S. T., & Charles, M. H. (2023) · Contemporary Diabetes · doi:10.1007/978-3-031-15613-7_2 · Cited by 17
Ponirakis, G., Al‐Janahi, I., Elgassim, E., Gad, H., Petropoulos, I. N., Khan, A., Ali, H. A., Siddique, M. A., Gul, W., Ferdousi, M., et al. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13864 · Cited by 19
Ziegler, D. (2020) · Der Internist · doi:10.1007/s00108-020-00770-8 · Cited by 19
Greco, C., Nascimbeni, F., Carubbi, F., Andreoné, P., Simoni, M., & Santi, D. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194466 · Cited by 20
Ishibashi, F., & Tavakoli, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00052 · Cited by 17
“In the United Kingdom Prospective Diabetes Study (UKPDS) (1), the intensive (HbA1c: 53.0 mmol/mol) and conventional GC (HbA1c: 62.8 mmol/mol) had a similar effect on DPN and CAN.”
BackgroundMethodInfluentialWeinrauch, L. A., D’Elia, J. A., Finn, P. V., Lewis, E. F., Desai, A. S., Claggett, B. L., Cooper, M. E., & McGill, J. B. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.12.021 · Cited by 14
Køhler, E., Dalgas, U., Buhl, C. S., & Brincks, J. (2024) · Physiotherapy Theory and Practice · doi:10.1080/09593985.2024.2391823 · Cited by 18
Cho, N. R., Yu, Y., Oh, C., Ko, D. S., Myung, K., Lee, Y., Na, H. S., & Kim, Y. H. (2021) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223211041936 · Cited by 13
Ponirakis, G., Abdul‐Ghani, M. A., Jayyousi, A., Zirie, M. A., Al‐Mohannadi, S., Almuhannadi, H., Petropoulos, I. N., Khan, A., Gad, H., Migahid, O., et al. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13582 · Cited by 11
Diagnosis of diabetic polyneuropathy in primary care
Khramilin, V. N., Strokov, I. A., Давыдов, О. С., & Churyukanov, M. V. (2021) · Russian Journal of Pain · doi:10.17116/pain20211902147 · Cited by 15
Jin, J., Wang, W., Gu, T., Chen, C., Sun, J., Chen, W., Bi, Y., & Zhu, D. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.02.007 · Cited by 12
Solomon, W., Hector, S. B., Raghubeer, S., Erasmus, R. T., Kengne, A. P., & Matsha, T. E. (2020) · Epigenomes · doi:10.3390/epigenomes4030019 · Cited by 13
“Treatment with metformin was shown to decrease the incidence of DPN as was observed by the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial [31].”
MethodA Study on Peripheral Neuropathy and Its Related Risk Factors Associated With hba1c Levels
Hossain, M., Sarkar, M., Mahbub, I., & Islam, S. (2021) · Journal of Bio-Science · doi:10.3329/jbs.v29i2.54961 · Cited by 14
“The vascular risk factors were found in develops DPN in Type-2 DM (Pop-Busui et al. 2013, Andersen et al. 2018, Callaghan et al. 2018).”
BackgroundLee, C. G., Ciarleglio, A., Edelstein, S. L., Crandall, J. P., Dabelea, D., Goldberg, R. B., Kahn, S. E., Knowler, W. C., Maxwell, T., White, N. H., et al. (2024) · Diabetes Care · doi:10.2337/dc23-2009 · Cited by 12
Catecholaminergic and opioidergic system mediated effects of reboxetine on diabetic neuropathic pain
Yücel, N. T., Can, Ö. D., & Özkay, Ü. D. (2020) · Psychopharmacology · doi:10.1007/s00213-019-05443-5 · Cited by 11
“Ensuring glycemic control with lifestyle changes and appropriate drug therapies are the most effective approaches to prevent diabetes-related neuropathic changes (Pop-Busui et al. 2013; Ang et al. 2014).”
BackgroundGavini, C. K., Bonomo, R. R., & Mansuy‐Aubert, V. (2020) · Scientific Reports · doi:10.1038/s41598-020-63357-1 · Cited by 10
Metadata
- Authors
- Pop-Busui, R., Lu, J., Brooks, M. M., Albert, S., Althouse, A. D., Escobedo, J., Green, J., Palumbo, P., Perkins, B. A., Whitehouse, F., Jones, T. L. Z., & for the BARI 2D Study Group
- Affiliations
- Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, Michigan
- University of Pittsburgh (US)
- Saint Louis University (US)
- Mexican Social Security Institute (MX)
- Duke University (US)
- Mayo Clinic (US)
- University of Toronto (CA)
- Henry Ford Health (US)
- National Institutes of Health (US)
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-09-14
- Volume
- 36
- Issue
- 10
- Pages
- 3208-3215
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3781573
- OpenAlex
- W2126800252
- Cited by
- 167
- References
- 38
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 15 · 2023: 13 · 2022: 12 · 2021: 24 · 2020: 25 · 2019: 11 · 2018: 21 · 2017: 5 · 2016: 8 · 2015: 7 · 2014: 7
- FWCI
- 5.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- Amylin Pharmaceuticals
- GlaxoSmithKline
- Sanofi
- Medtronic
- European Foundation for the Study of Diabetes
- Novo Nordisk
- National Institutes of Health
- National Heart, Lung, and Blood Institute (U01HL063804, U01HL061748, U01HL061744, U01HL061746)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK020572)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- diabetic peripheral neuropathy, glycemic control, insulin sensitizers, insulin therapy, type 2 diabetes, BARI 2D trial, neuropathy incidence, neuropathy prevalence, sex differences, Michigan Neuropathy Screening Instrument, coronary artery disease
- MeSH terms
- Aged, Blood Glucose, Diabetes Mellitus, Type 2, Diabetic Neuropathies, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Peripheral Nervous System Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.